Greystone Associates Analyzes Technology and Therapeutic Factors Influencing Growth of Dry Powder Inhalers

Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS) has a pharmacodynamic and pharmacokinetic profile that is comparable to the dry powder inhaler (DPI) formulation of formoterol fumarate, Foradil® Aerolizer® 12 µg (FA).

Greystone Associates Analyzes Evolving Device Technologies and Emerging Therapeutic Options.

New Analysis by Applied Data Research Examines Recent Developments and Assesses Market Impact

User Acceptance and Compliance Linked to Dosing-Specific Packaging